Bonneville R et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 2017;1:1-15. Abstract

Cheng A-L et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). ASCO 2017;Abstract 4001.

Green AK et al. A review of immune checkpoint blockade therapy in endometrial cancer. ASCO Educational Book 2020;40:238-44. Abstract

Ikeda K et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017;52(4):512-9. Abstract

Konstantinopoulos PA et al. TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. ASCO 2018;Abstract 106.

Makker V et al. Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification. ASCO 2022;Abstract 5511.

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract

Oaknin A. Novel Immunotherapy in Endometrial Cancer. Education Session. ASCO 2022. https://meetings.asco.org/abstracts-presentations/204275/slides.

Vergote I et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. J Clin Oncol 2023;41(35):5400-10. Abstract